SCHEMBL1444029

SCHEMBL1444029

C=CC(NN)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 6/20 0.42
DPP4 P27487 2/20 0.39
F2 P00734 1/20 0.39
CTSD P07339 1/20 0.38
HTR2A P28223 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL342906 0.98 AOC3 (0.41) AOC3DPP4F2CTSDHTR2A
SCHEMBL9268820 0.81 SMN1; SMN2 (0.37) DPP4F2HTR2ATAAR1SMN1; SMN2
SCHEMBL9416672 0.77 SMN1; SMN2 (0.35) DPP4F2SMN1; SMN2CYP2C19ALDH1A1
SCHEMBL897649 0.77 KDM4E (0.38) DPP4F2SMN1; SMN2CYP2C19ALDH1A1
Ammonia Solution, Strong SCHEMBL27951261 0.77 HDAC1 (0.39) SMN1; SMN2CYP2C19ALDH1A1KDM4ECYP3A4
SCHEMBL9631266 0.77 CYP3A4 (0.35) DPP4F2HTR2ATAAR1SMN1; SMN2
SCHEMBL2028407 0.77 ALDH1A1 (0.46) HTR2ATAAR1SMN1; SMN2CYP2C19ALDH1A1
SCHEMBL9631211 0.77 ALDH1A1 (0.39) DPP4F2SMN1; SMN2CYP2C19ALDH1A1
SCHEMBL5440741 0.76 TDP1 (0.43) CTSDSMN1; SMN2CYP2C19ALDH1A1KDM4E
SCHEMBL13296205 0.76 RAB9A (0.41) DPP4F2SMN1; SMN2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4919916-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1990-04-24 US claimed
US-4786653-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1988-11-22 US claimed
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2024-06-13 US disclosed
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2022-12-29 US disclosed
CN-110003172-B Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators 同步制药公司 2022-04-01 CN disclosed
EP-3939971-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. (US) 2022-01-19 EP disclosed
CN-107674071-B Carbazole-containing sulfonamides as cryptochrome modulators 同步制药公司 2021-12-31 CN disclosed
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2021-06-10 US disclosed
EP-3129366-B1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYNCHRONICITY PHARMA INC (US) 2021-06-09 EP disclosed
EP-3777846-A1 VAP-1 INHIBITORS FOR TREATING PAIN BenevolentAI Cambridge Limited (GB) 2021-02-17 EP disclosed
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. (US) 2020-09-01 US disclosed
US-20030181516-A1 Substance with sedative effect TECHNOLOGY COMMERCIALIZATION CORP. 2003-09-25 US disclosed
US-5428063-A For treating or preventing fatty infiltration, the first stage of cirrhosis BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1995-06-27 US disclosed
US-5219858-A Method and compositions for effecting withdrawal from drug dependency PARNELL PHARMACEUTICALS, INC. (US) 1993-06-15 US disclosed
US-5051426-A Method for effecting withdrawal from drug dependency PARNELL PHARMACEUTICALS, INC. (US) 1991-09-24 US disclosed
US-5017602-A Antidotes for nerve gas, herbicides, insecticides UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1991-05-21 US disclosed
US-4919916-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1990-04-24 US disclosed
US-4919916-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1990-04-24 US disclosed
US-4786653-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1988-11-22 US disclosed
US-4786653-A Treatment of neurotransmitter-linked drug abuse GOLWYN DANIEL H (US) 1988-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS AOC3 3171/4885DPP4 611/4885F2 635/4885
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators CRY1, CRY2, HCCS AOC3 3171/4885DPP4 611/4885F2 635/4885
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS AOC3 3171/4885DPP4 611/4885F2 635/4885
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS AOC3 3171/4885DPP4 611/4885F2 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.